Did you know, when your blood pressure is too high, even when treated with medication, it can increase your risk of cardiovascular disease? Find out more about the ZENITH study for people with uncontrolled high blood pressure.
HomeStudies
Studies
Consider joining a clinical study If you have high blood pressure, diabetes and cardiovascular disease, our clinical study could be a good fit for you. While lifestyle changes and current medicines offer some protection, many people with these conditions still experience disease progression that increases their risk of further cardiovascular complications and kidney damage.
Learn about a clinical study for healthy women ages 16-26. Human papilloma virus (HPV) can cause anal and genital diseases. Vaccines can protect against diseases caused by HPV.
Why might I want to take part? Keeping your low-density lipoprotein (LDL) cholesterol (“bad cholesterol”) levels under control is very important to reduce the risk of cardiovascular problems like a heart attack or stroke. But many people do not get enough benefit from existing medications, and need new, convenient treatment options.
Introducing a clinical trial for adults and adolescents 12+, including those who are at increased risk of severe illness from COVID-19.
Who can take part?
This study is enrolling participants who:
Are at least 65 years of age, OR are 12-64 years of age and have at least 1 of the following medical conditions:
•Asthma
•Diabetes I or II
•Heart conditions such as previous coronary artery disease, heart failure, or cardiomyopathy
•Cancer
•Cerebrovascular disease (stroke)
•Chronic kidney, lung, or liver disease
•Cystic fibrosis
•Disabilities such as cerebral palsy, autism, ADHD, Down syndrome, other chromosomal disorders, etc.
•Physical inactivity (10 minutes per week or less)
•Tuberculosis
•Weakened immune system
•HIV
•Depression or schizophrenia spectrum disorders
•Parkinson’s disease or dementia
•Obesity (BMI ≥30 or ≥95th percentile in children)
•Current or former smoker
Have never received a COVID-19 vaccine or received a COVID-19 vaccine more than 5 months ago, and have not been diagnosed with COVID-19 within the last 5 months.
Do not have a history of a severe reaction associated with any vaccine or vaccine component.
There will be other requirements that the study team will discuss with you.
What to expect
All participants will receive 1 dose of the study vaccine as an injection in the upper arm.
Study duration
Participation lasts for about 6 months.
Study visits
Participants will have at least 3 visits with the study team.
Study-related costs
There is no cost to participate in this study, and health insurance is not required. Participants will also be paid for completing study-related activities.
About the study vaccine
The study vaccine is a modified version of Pfizer and BioNTech’s original mRNA-based COVID-19 vaccine, which has been authorized for use in more than 149 countries. The modified formulation is designed to improve protection against Omicron LP.8.1, the COVID-19 variant recommended by the Food and Drug Administration (FDA) for the 2025-2026 respiratory virus season.
Safety is our top priority
Before you or your child chooses to participate, you will be given all the details about the clinical trial, including potential benefits and risks. Participants’ health will be closely monitored throughout the study.
Pursuing updated protection against COVID-19
Staying up to date on your COVID-19 vaccines is still the best way to prevent severe illness, especially for those with certain risk factors. However, as the virus continues to change, vaccines must evolve as well. That’s why we’re developing an updated COVID-19 vaccine for the 2025-2026 respiratory virus season.
About this clinical trial
This clinical trial will help us learn if an investigational formulation of our COVID-19 vaccine is safe, and if it can help the body produce antibodies to fight off new variants of the COVID-19 virus.
Your participation in this clinical trial will contribute to the development of an updated COVID-19 vaccine that may increase protection for millions of people around the world. So,
thank you for taking the time to learn more.
Tomorrow’s breakthroughs start today with you
Participation by people of all backgrounds is critical to developing vaccines that protect against COVID-19. The greater the representation among clinical trial participants, the more we can learn about potential vaccines and how they work for different people. Your participation could make a difference.
Ready to learn more?
For more information, reach out to our study team.
786-772-0510
Learn about a clinical trial for early Alzheimer’s disease.
What is the goal of this trial?
This trial is testing an investigational drug called MK-2214 in people who have early Alzheimer’s disease. Researchers want to learn about the safety of the investigational drug, MK-2214, and how well it may work to slow the progression of Alzheimer’s disease.
Who can join this clinical trial?
You may be able to join if you are 50-85 years of age and:
● Have mild cognitive impairment or mild dementia due to Alzheimer’s disease
● Have a person (trial partner) who can go with you to specific trial visits and:
➤ Knows you well
➤ Is in regular contact with you
➤ Can answer questions about you
Participants are allowed to continue taking certain medicines for Alzheimer’s disease (including, but not limited to, brexpiprazole, donepezil, rivastigmine, galantamine, and
memantine) as long as the dose has not changed for at least 3 months.
The trial doctor will talk with you about more requirements to join this trial.
What will happen during this clinical trial?
If you qualify and decide to participate, you will be in the trial for about 2.5 years and visit the trial site about once a month.
Participants get the trial drugs, tests, and exams at no cost.
To learn more about this clinical trial, including risks and possible benefits of joining, please contact: 786-772-0510
Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
Flu virus changes every year, and that’s why yearly vaccination is the most effective way to help prevent flu and its complications.
The FLU SV MRNA-028 study is testing a new mRNA-based vaccine designed to protect against multiple flu virus strains, including those that may differ from the predicted strains.
This study will evaluate whether the investigational vaccine provides sufficient or better protection against seasonal flu compared to current vaccines, for participants who are more than 18 years of age.
Our vaccine aims to enhance the immune system’s ability to recognize and fight off multiple flu virus strains. This may reduce the severity of the illness and provide better defence, even when the vaccine isn’t an exact match for the flu strains circulating in a particular year.
If you are 18 years of age or older and would like to learn more about this study, please speak to your doctor.
Taking part in a clinical trial is voluntary. You are free to leave at any time and do not need to provide a reason.
Researchers want to understand how well an investigational medication, given along with current asthma treatment, may help to reduce asthma symptoms. Respond today to learn more.
Facts to know about asthma:
• Nearly 28 million people in the U.S. have asthma — about 1 in 12 people.
• Symptoms include shortness of breath, wheezing, coughing and tightness or pain in the chest.
• Asthma can be triggered by different things for different people — common allergens include seasonal pollen, mold spores, dust or pet dander.
Are you or someone you know frustrated with asthma that’s not in control?
Meet with an asthma research doctor!
Exclusive Opportunity: Limited Spots Available for a New Asthma Study!
Key Qualifications
• 18 and 75 years old
• Diagnosed with asthma
• Use regular daily inhaler to manage asthma symptoms
What to Expect if You Qualify
• Meet with a study doctor and complete health-related assessments
• Participate in 12 in-person visits over 15 months
• Access to study medication at no cost
• Reimbursement may be available for your time and effort
See if you qualify!
Call us: 786-772-0510
Around 1 in 5 people inherit a raised level of a sticky particle called Lp(a) [or lipoprotein(a)] that can increase their risk of heart disease and heart damage.1
You could be one of them. There are currently no approved medications that directly target Lp(a) levels, but we want to change that. If you’re taking medication for your heart health and either have or are at risk of developing heart disease, contact our study team to learn more about getting your Lp(a) level tested and the opportunity to take part in important clinical research.
This could be your chance to potentially target a risk factor that is unable to be controlled with lifestyle changes and other medicines.
1. Rhainds D, Brodeur MR, Tardif JC. Lipoprotein (a): When to measure and how to treat? Curr Atheroscler Rep. 2021;23(9):51. Doi:10.1007/s11883-021-00951-2.
The RSVital Trial is evaluating an investigational vaccine, called mRNA-1345, to determine if it may provide additional protection against RSV in adults aged 60 and older when given as a revaccination.
Indago delivers community-based services for Miami and neighboring areas, driving advances in investigational research for new and improved drugs.
Working Hours
Monday-Friday 8:00 AM – 5:00 PM
Saturday (open if necessary)
Sunday (open if necessary)